Advanced Micro Devices
AMD
ASML Holding
ASML
Meta Platforms
META
Cisco
CSCO
Intel
INTC
US Stock MarketDetailed Quotes
GLUE Monte Rosa Therapeutics
- 7.060
- -0.160-2.22%
Close Dec 27 16:00 ET
- 7.400
- +0.340+4.82%
Post 20:01 ET
433.74MMarket Cap-3.97P/E (TTM)
7.320High6.860Low828.72KVolume7.150Open7.220Pre Close5.81MTurnover2.24%Turnover RatioLossP/E (Static)61.44MShares12.40052wk High2.11P/B260.90MFloat Cap3.21052wk Low--Dividend TTM36.95MShs Float45.560Historical High--Div YieldTTM6.37%Amplitude2.440Historical Low7.005Avg Price1Lot Size
Monte Rosa Therapeutics News
Wells Fargo Downgrades Monte Rosa Therapeutics(GLUE.US) to Hold Rating, Cuts Target Price to $11
Wells Fargo Downgrades Monte Rosa Therapeutics to Equal-Weight, Lowers Price Target to $11
Monte Rosa Therapeutics Analyst Ratings
Press Release: Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
Express News | Monte Rosa Therapeutics Appoints DR. Eric a. Hughes to Board of Directors
Monte Rosa Closes Global License Agreement With Novartis
Monte Rosa Therapeutics Announced It Will Present Preclinical Data On The Potential Of Its Highly Selective Cyclin-dependent Kinase 2 (Cdk2)-directed Molecular Glue Degrader To Treat Hr-positive/Her2-negative Breast Cancer At The 2024 San Antonio...
Express News | Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis to Advance T and B Cell-Modulating Vav1-Directed Molecular Glue Degraders
Monte Rosa Therapeutics Announces Closing of Global License Agreement With Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Monte Rosa Therapeutics (GLUE) and CAMP4 Therapeutics Corporation (CAMP)
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $20
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $14
Analysts' Top Healthcare Picks: Insulet (PODD), Monte Rosa Therapeutics (GLUE)
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $20
Express News | Monte Rosa Therapeutics Inc: Recommended Phase 2 Dose Determined as 0.5 Mg Daily at a 21 Days on, 7 Days off Drug Dosing Schedule
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients With MYC-driven Solid Tumors
Express News | Monte Rosa Therapeutics Provides Development Progress Update for Ongoing Mrt-2359 Phase 1/2 Study in Patients With Myc-Driven Solid Tumors
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
Owning 47% Shares,institutional Owners Seem Interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.